Imunon shares rise 10.06% after-hours after announcing $7 million registered direct offering to fund R&D and operations.

Imunon surged 10.06% in after-hours trading following the announcement of a $7.0 million registered direct offering with an undisclosed healthcare-focused institutional investor. The financing, comprising shares, pre-funded warrants, and exercisable warrants priced at $3.61–$3.6099 per unit, will fund R&D, capital expenditures, and working capital. The transaction, executed on December 29, 2025, and disclosed via an 8-K filing, signals investor confidence in the biotech firm’s growth prospects, as immediate warrant exercisability and a five-year term for standard warrants further enhance liquidity potential. The after-hours rally reflects market optimism over the secured capital infusion to advance corporate initiatives.